LC
AURA icon

Lindbrook Capital’s Aura Biosciences AURA Stock Holding History

Lindbrook Capital’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$820 Buy
+140
New +$1.06K ﹤0.01% 2517

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Lindbrook Capital's AURA Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Aura Biosciences (AURA) in Q1 2025: 140 shares worth $820. The stake represents ﹤0.01% of the portfolio and ranks #2517 among its holdings.

94 funds tracked by Wall St. Rank hold AURA as of Q1 2025.

  • Lindbrook Capital held 140 shares of Aura Biosciences worth $820 as of Q1 2025.
  • Aura Biosciences was a new Lindbrook Capital position in Q1 2025.
  • Aura Biosciences made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2517 holding.
  • 94 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.